secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0000950170-25-027707
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines Q4 2024 net loss $194.6M, cash $2.3B; Phase 3 PDAC enrollment target 2025
--------------------------------------------------------------------------------

- Q4 net loss $194.6M vs $161.5M YoY; full year net loss $600.1M vs $436.4M.
- Cash and securities $2.3B at Dec 31, 2024, up from $1.9B; $823M net raised in Dec 2024 public offering.
- 2025 GAAP net loss guidance $840M-$900M; cash runway expected into H2 2027.
- Expects to complete enrollment in Phase 3 RASolute 302 (PDAC) in 2025 for data readout in 2026; Phase 3 RASolve 301 (NSCLC) now activating sites.
- Plans to initiate two additional registrational trials for daraxonrasib in earlier-line PDAC in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000095017025027707/0000950170-25-027707-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000095017025027707/rvmd-20250226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-027707

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer